Spectrum Pharmaceuticals (SPPI) Now Covered by Analysts at B. Riley

B. Riley initiated coverage on shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) in a research note published on Monday, December 18th, MarketBeat reports. The firm issued a buy rating and a $26.00 price objective on the biotechnology company’s stock.

A number of other analysts also recently weighed in on SPPI. Jefferies Group upped their target price on shares of Spectrum Pharmaceuticals from $9.00 to $13.00 and gave the stock a buy rating in a research report on Monday, September 25th. Zacks Investment Research downgraded shares of Spectrum Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, October 4th. HC Wainwright reaffirmed a buy rating and issued a $14.00 target price on shares of Spectrum Pharmaceuticals in a research report on Thursday, September 14th. Finally, Guggenheim assumed coverage on shares of Spectrum Pharmaceuticals in a research report on Monday, October 23rd. They issued a buy rating and a $32.00 target price on the stock. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Spectrum Pharmaceuticals has a consensus rating of Buy and a consensus target price of $22.17.

Shares of Spectrum Pharmaceuticals (NASDAQ SPPI) traded up $0.12 during midday trading on Monday, reaching $19.42. 557,500 shares of the company’s stock traded hands, compared to its average volume of 1,240,000. The company has a quick ratio of 4.89, a current ratio of 5.04 and a debt-to-equity ratio of 0.33. Spectrum Pharmaceuticals has a 1-year low of $4.31 and a 1-year high of $21.95. The company has a market cap of $1,950.00, a price-to-earnings ratio of -19.42 and a beta of 1.63.

Spectrum Pharmaceuticals (NASDAQ:SPPI) last issued its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.22) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.06). Spectrum Pharmaceuticals had a negative return on equity of 29.73% and a negative net margin of 58.94%. The company had revenue of $36.40 million during the quarter, compared to the consensus estimate of $33.27 million. During the same quarter last year, the company posted ($0.07) earnings per share. The firm’s revenue for the quarter was up 9.0% compared to the same quarter last year. research analysts expect that Spectrum Pharmaceuticals will post -1.03 EPS for the current year.

A number of hedge funds have recently made changes to their positions in the stock. Jane Street Group LLC bought a new position in Spectrum Pharmaceuticals during the 3rd quarter valued at about $152,000. OxFORD Asset Management LLP bought a new position in Spectrum Pharmaceuticals during the 3rd quarter valued at about $2,149,000. Hartford Investment Management Co. bought a new position in Spectrum Pharmaceuticals during the 3rd quarter valued at about $317,000. Schwab Charles Investment Management Inc. lifted its stake in Spectrum Pharmaceuticals by 16.2% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 505,909 shares of the biotechnology company’s stock valued at $7,119,000 after acquiring an additional 70,487 shares during the period. Finally, WINTON GROUP Ltd bought a new position in Spectrum Pharmaceuticals during the 3rd quarter valued at about $3,263,000. 71.87% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Spectrum Pharmaceuticals (SPPI) Now Covered by Analysts at B. Riley” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://stocknewstimes.com/2018/01/12/spectrum-pharmaceuticals-sppi-earns-buy-rating-from-analysts-at-b-riley.html.

About Spectrum Pharmaceuticals

Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).

Analyst Recommendations for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Receive News & Ratings for Spectrum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply